An observational study in Acute Respiratory Infection, Sepsis and Postoperative Respiratory Distress, sponsored by South West Sydney Local Health District. Status unknown at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-18.
Sponsored by South West Sydney Local Health District · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Sepsis with a site in Australia — 7 open to participants now, 8 under way, 1 of them phase 3. Sepsis · Australia.
Among the 47 studies in Sepsis with a site in Australia, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, and was the 39th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →7 of the 47 studies in Sepsis with a site in Australia are open now. Recruiting first, the newest first:
The George Institute · Sites in Australia
Ages 18+
National University of Singapore · Sites in Australia, China, Lebanon and 9 more countries
Ages 18+
Todd C. Lee MD MPH FIDSA · Sites in Australia, Canada, New Zealand
Ages 18+
Murdoch Childrens Research Institute · Sites in Australia
Ages 0 days–90 days
Anders Aneman · Sites in Australia
Ages 18+ · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 15 · Phase 4 8
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 316 across the 35 interventional studies, 414 across the 11 observational. Of the 32 that completed or were terminated, 9 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 47 have an industry lead sponsor. The 10 most frequent:
South West Sydney Local Health District is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
South West Sydney Local Health District has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770622Murdoch Childrens Research InstituteImproving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Sepsis with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Capnodynamic monitoring has the potential to offer continuous and non-invasive measurements of heart and lung function in patients requiring ventilation in an intensive care setting. Since mechanical ventilation with full patient synchronization is commonly used in ICU, capnodynamic monitoring can be immediately embedded in clinical care and compared to current methods of monitoring cardiac output, lung volumes and oxygen delivery. This observational study will explore capnodynamic monitoring in mechanically ventilated patients with a range of cardiorespiratory compromise.
This study aims to:
Patients admitted to ICU for mechanical ventilation with a diagnosis of viral/bacterial pneumonia, sepsis or following cardiac surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Respiratory tract infection:
Sepsis:
Cardiac surgery:
Exclusion Criteria:
In all cohorts:
Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support
Device: Capnodynamic monitoring
Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support
Device: Capnodynamic monitoring
Patients admitted to ICU for mechanical ventilatory support following cardiac surgery
Device: Capnodynamic monitoring
In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation: ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.
Also known as: thermodilution cardiac output measurement, echocardiography, blood gas analyses
Correlation between capnodynamic effective pulmonary blood flow and cardiac output measured by pulmonary artery thermodilution or echocardiography
Capnodynamic measurements of effective pulmonary blood flow are compared with contemporaneously obtained cardiac output measurements using clinical reference methods
Time frame: Through study completion, an average of 1 year
Correlation between capnodynamic estimates of mixed venous oxygen saturation and blood gas analysis of blood obtained from the pulmonary artery pulmonary.
Capnodynamic estimates of mixed venous oxygen saturation are compared with contemporaneously obtained blood gases from the pulmonary artery catheter
Time frame: Through study completion, an average of 1 year
Prediction by capnodynamic monitoring of combined changes in end expiratory lung volume and effective pulmonary blood flow to assess changes in pulmonary gas exchange during various levels of PEEP
At three different levels of PEEP, the interactions between end expiratory lung volume and effective pulmonary blood flow will be assessed and correlated to changes in arterial partial pressure of oxygen and carbon dioxide
Time frame: Through study completion, an average of 1 year
Plan to share: Undecided — Upon reasonable request, IPD may be shared if fully compliant with HREC requirements and European GRDP regulations
Started Feb 2021 (actual). Primary completion is estimated for Dec 2022, 22 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 22 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South West Sydney Local Health District